Ferns, defined by large genomes, high chromosome counts, and pervasive aneuploidy as well as intraspecific polyploid ...

The symposium also marked the formal unveiling of Metropolis' Centre of Genomics to the clinician community, reinforcing the Company's broader clinical engagement initiative focused on embedding ...

Record consumable revenue in Q4 was driven by meaningful traction in clinical sequencing applications, particularly whole ...

Ibrutinib was a breakthrough when it was first approved to treat R/R MCL in 2013, and a year later for patients with at least 1 prior treatment for chronic lymphocytic leukemia. However, its ...

Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.

A new study, recently published in the journal Nature Communications, is leading to a new understanding of how immune cells ...

The FDA has granted priority review to the supplemental biologics license application for datopotamab deruxtecan (Dato-DXd) ...

Azenta, Inc. (NASDAQ:AZTA) Q1 2026 Earnings Call Transcript February 4, 2026 Azenta, Inc. misses on earnings expectations.

With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.

Since the launch of the Hong Kong laboratory in July 2025, Omics Empower has supported research teams with local single-cell sequencing and spatial transcriptomics services. Faster processing helps ...

IAMGOLD Corporation IAG is slated to report fourth-quarter 2025 results after market close on Feb. 17. The company’s ...

Zenocutuzumab--zbco, marketed as BIZENGRI (R), received Breakthrough Therapy Designation from the FDA in October 2025 and was granted accelerated approval in December 2024 for adults with advanced ...